Pharmaceuticals News and Research

RSS

Understanding how key decision makers assess prescription drugs for health plan coverage

As medical advancements and an expanding pharmaceutical industry bring new prescription drugs into the market, deciding which ones to cover is becoming an even more difficult choice for health plans to make. How those decisions are made - and what information is used in the process - was the focus of a recent study by researchers at RTI International.

5 Apr 2012

Results from Abbott’s multiple interferon-free Phase 2 HCV studies to be presented at ILC 2012

Abbott will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV) at the International Liver Congress 2012 (ILC 2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain.

5 Apr 2012

BIND announces data from BIND-014 Phase 1 trials on prostate cancer

Nanomedicine research at the David H. Koch Institute for Integrative Cancer Research at MIT funded by a $5 million grant from the Prostate Cancer Foundation (PCF) has delivered the first nanomedicine shown to successfully target prostate cancer cells and deliver docetaxel chemotherapy in high concentrations in Phase I clinical trials.

5 Apr 2012

BIND presents results from BIND-014 Phase 1 trial on solid tumors at AACR 2012

BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called Accurins, announced today the presentation of late-breaker clinical data for BIND-014, the lead drug candidate within a new class of targeted therapeutics that are programmed to concentrate at tumors, at the American Association for Cancer Research (AACR) 2012 Annual Meeting.

5 Apr 2012

µ-PIIIA conotoxin can be effective in controlling cancer pain

Hidden in the mud, the cone snail Conus purpurascens lies in wait for its victims. It attracts its prey, fish, with its proboscis, which can move like a worm, protruding from the mud. Once a fish approaches out of curiosity, the snail will rapidly shoot a harpoon at it, which consists of an evolutionarily modified tooth. The paralyzed victim then becomes an easy meal. It takes the venomous cone snail about two weeks to digest a fish. During this time, its venomous harpoon is also replaced.

5 Apr 2012

FTC approval of Express Scripts-Medco merger triggers new battlegrounds

Drug Stores and community pharmacists have pledged to fight on in the courts, but some consumer advocates see a silver lining in the merger.

4 Apr 2012

TL32711 compound targets key pathway in lymphoma

Scientists at Fox Chase Cancer Center in Philadelphia have come one step closer to developing the first treatment to target a key pathway in lymphoma. The new findings will be announced at the AACR Annual Meeting 2012 on Tuesday, April 3.

4 Apr 2012

Dohmen announces acquisition of BioSoteria

CEO Cynthia (Dohmen) LaConte announced today that the Dohmen Company has acquired BioSoteria, a leading provider of drug safety and risk management services to the biopharmaceutical industry.

4 Apr 2012

FDA clears Fenwal's Aurora plasmapheresis system

The U.S. Food and Drug Administration has cleared for marketing a new source plasma collection system developed by Fenwal, Inc., the company announced today. Called the Aurora plasmapheresis system, the new device can support two-way, wireless data communication designed to eliminate manual steps and increase operator and donor satisfaction.

4 Apr 2012

BioScale presents data on phospho-protein analysis of MAP kinase pathway activation state at 103rd AACR

BioScale, Inc. a life science company that develops ultrasensitive protein analysis technology, presented findings of recently completed research studies on phospho-protein analysis of the activation state of the MAP kinase pathway at the 103rd Annual Meeting of the American Association for Cancer Research (AACR), held at McCormick Place in Chicago, Illinois, March 31 - April 4, 2012.

3 Apr 2012

Onyx announces results from regorafenib Phase 3 trial on GIST

Onyx Pharmaceuticals, Inc. today announced results from the Phase 3 trial GRID (GIST – Regorafenib in Progressive Disease) evaluating the investigational compound regorafenib (BAY 73-4506), a Bayer-owned compound, for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib.

3 Apr 2012

TLR4/MD-2 protein complex triggers morphine-induced inflammation

A University of Colorado Boulder-led research team has discovered that two protein receptors in the central nervous system team up to respond to morphine and cause unwanted neuroinflammation, a finding with implications for improving the efficacy of the widely used painkiller while decreasing its abuse potential.

3 Apr 2012

NutraGene introduces first ever commercial type 2 diabetes genetic test

With the launch of the country's first ever commercial genetic test for type 2 diabetes, Indians will now have access to clinically relevant and cost effective genetic risk assessment services. NutraGene, a Delhi based genomics company that launched the tests believes that its type 2 diabetes genetic test will provide physicians an effective tool in assessing the risk of diabetes in the Indian population and will help in implementing personalized prevention and management strategies.

3 Apr 2012

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

ARIAD Pharmaceuticals, Inc. today announced the presentation of new preclinical data on its investigational pan-BCR-ABL inhibitor, ponatinib, and its investigational dual EGFR-ALK inhibitor, AP26113, at the American Association for Cancer Research Annual Meeting in Chicago.

3 Apr 2012

RPS selects DATATRAK as preferred vendor

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced RPS selected DATATRAK as a preferred vendor and joined DATATRAK's CRO Connect Partner program.

3 Apr 2012

Teva reports successful outcome of three debut financings

Teva Pharmaceutical Industries Limited announced today that it successfully priced its debut EUR 1 billion and CHF 450 million debt offerings, and that it entered into a JPY 100 billion senior unsecured fixed-rate syndicated term loan facility.

2 Apr 2012

Novel tetracyclines with improved potency, efficacy against contemporary P. aeruginosa isolates

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results from studies that demonstrate the improved potency and pharmacokinetics of several of its newest discovery-stage tetracycline analogs.

2 Apr 2012

Ampio, Australian TGA reach agreement over Zertane submission plan

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, announced today that it reached agreement with the Therapeutic Goods Administration, Canberra, Australia, on a plan of drug manufacture and quality control for Zertane and the overall plan for the preparation of Common Technical Documents for the draft registration submission expected to be filed in June 2012.

2 Apr 2012

Inovio awarded U.S. DOD grant to advance non-invasive surface electroporation delivery device

Inovio Pharmaceuticals, Inc. announced today it has received a U.S. Department of Defense Small Business Innovation Research Grant to advance the development of a low-cost, non-invasive surface electroporation (EP) delivery device and test its utility in combination with Inovio's novel synthetic DNA vaccines against viruses with bioterrorism potential, including hanta, puumala, arenavirus and pandemic influenza.

2 Apr 2012

Blocking PRC2 protein may help protect against AML

Scientists at Cold Spring Harbor Laboratory have identified a candidate drug target for treating acute myeloid leukemia, a white blood cell cancer that proliferates out of control in the bone marrow.

2 Apr 2012